[{"id":"3aa72670-9b0b-4205-9807-1cc48204caf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05335941","created_at":"2022-04-20T16:53:38.622Z","updated_at":"2025-02-25T15:35:35.713Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma","source_id_and_acronym":"NCT05335941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MTAP • IL17A","pipe":"","alterations":" ","tags":["MTAP • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-10"},{"id":"f3c62253-8046-49b1-bb25-cd529c350b91","acronym":"MORPHEUS-PDAC","url":"https://clinicaltrials.gov/study/NCT03193190","created_at":"2021-01-18T15:44:27.682Z","updated_at":"2025-02-25T16:36:54.744Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","source_id_and_acronym":"NCT03193190 - MORPHEUS-PDAC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2025-02-06"},{"id":"607d2950-c677-467b-8196-ea2b0e2b9d8e","acronym":"VELOCITY-Lung","url":"https://clinicaltrials.gov/study/NCT05633667","created_at":"2022-12-01T15:57:15.119Z","updated_at":"2024-07-02T16:34:58.933Z","phase":"Phase 2","brief_title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","source_id_and_acronym":"NCT05633667 - VELOCITY-Lung","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 397","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-04"},{"id":"15f2feeb-91bd-4d1e-8210-eb0dea4872da","acronym":"ARC-7","url":"https://clinicaltrials.gov/study/NCT04262856","created_at":"2021-01-18T20:42:57.527Z","updated_at":"2024-07-02T16:35:00.997Z","phase":"Phase 2","brief_title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04262856 - ARC-7","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-24"},{"id":"409dc71f-d788-44b0-9225-6f9acd37a635","acronym":"ARC-4","url":"https://clinicaltrials.gov/study/NCT03846310","created_at":"2021-01-18T18:59:18.192Z","updated_at":"2024-07-02T16:35:01.028Z","phase":"Phase 1","brief_title":"A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer","source_id_and_acronym":"NCT03846310 - ARC-4","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-24"},{"id":"e5aa0f89-24de-40bf-8a67-186c3db1a88b","acronym":"ARC-2","url":"https://clinicaltrials.gov/study/NCT03719326","created_at":"2021-01-18T18:13:45.819Z","updated_at":"2024-07-02T16:35:01.152Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","source_id_and_acronym":"NCT03719326 - ARC-2","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2024-05-24"},{"id":"f5b1a6c8-e4d4-430b-b708-74c9cb48dc4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04791839","created_at":"2021-03-10T12:55:03.832Z","updated_at":"2024-07-02T16:35:10.680Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04791839","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2024-04-09"}]